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Abstract
The recent large genotyping studies have identified a new repertoire of disease susceptibility loci of unknown function,
characterized by high allele frequencies and low relative risks, lending support to the common disease-common variant
(CDCV) hypothesis. The variants explain a much larger proportion of the disease etiology, measured by the population
attributable fraction, than of the familial risk. We show here that if the identified polymorphisms were markers of rarer
functional alleles they would explain a much larger proportion of the familial risk. For example, in a plausible scenario where
the marker is 10 times more common than the causative allele, the excess familial risk of the causative allele is over 10 times
higher than that of the marker allele. However, the population attributable fractions of the two alleles are equal. The
penetrance mode of the causative locus may be very difficult to deduce from the apparent penetrance mode of the marker
locus.
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Introduction
The common disease-common variant (CDCV) hypothesis
posits that common, interacting disease alleles underlie most
common diseases, perhaps in association with environmental
factors [1,2]. This hypothesis has been the scientific paradigm for
genome-wide association (GWA) studies that have been or are
being conducted on many common diseases. Numbers of new
susceptibility loci are being identified. For example, the recent
study by the Wellcome Trust Case Control Consortium detected
24 independent association signals for 7 major diseases [3]. For
prostate cancer, many independent susceptibility loci have been
described, one of which also predisposes to colorectal cancer [4–
11]. Typically, the detected variants are common, with a
frequency (p) higher than 10%, they are associated with low
genotype relative risk (GRR), they explain a large proportion of
the disease occurrence (described by the population attributable
fraction, PAF), they explain a tiny fraction of the familial risks
(quantified by e.g., the sibling relative risk ls) and, notably, they
are located in non-coding regions and the function of most
identified variants is unknown [5,7,12,13]. The search for
functionality at many of the verified loci, such as 8q24 in prostate
cancer, has revealed no clues to the mechanism of action [4–6].
The disparity between the high PAFs explained by the identified
loci, approaching 100% for some diseases, and the low ls
attributable to the detected associations has been noticed before
[2,3,14]. For example for breast cancer, the joint PAF of the
identified genes/loci is over 60% but they explain less than 30% of
the familial aggregation [15–17]; for prostate cancer, no more
than 15% of familial risk is explained [11], although the joint PAF
is probably 100% considering the independent 8q24 signals and
the large numbers of loci reported in the March 2008 issue of
Nature Genetics [5,6,9–11]. These discrepancies appear [18] to
challenge the CDCV paradigm, because the genes with a large
population impact, PAF, also eventually need to explain the
familial aggregation of the disease [14].
We test here a hypothesis that may help to understand the
paradox of high PAFs and low ls. When the identified marker
polymorphism is linked to a functional locus, the PAF for the
functional ‘causative’ allele is equal to the PAF for the marker, but
the familial risk attributable to the causative allele increases in
concert with the rarity of the variant and its increasing GRR. In
order to test the hypothesis, we model genetic parameters in terms
of a marker and a causative allele and translate these into PAFs
and ls [19].
Results
Fig. 1 shows a scheme on gene identification based on linkage
disequilibrium. It is assumed that the marker allele M tags the
causative variant C so that M is more frequent than C but C is
always found together with M, i.e., D9=1.0. There are thus three
haplotypes, c-m, c-M and C-M. The association signal for M is
entirely due to the functional effect of C. The example shown in
Table 1 assumes that M is common and that the frequency of C is
1/10 of that of M (pM=0.5, pC=0.05). We further assume
dominant penetrance for C (GRRC_Hom=GRRC_Het) and
D9=1.0. When the true GRR of the causative allele C is 1.5,
the GRR of M is 1.10 for homozygotes and 1.05 for heterozygotes.
The explained familial risks would be 1.01 for C and 1.00 for M.
Notably, PAF is 4.6% and it is equal for C and M. If the GRR for
C equals 10, the GRRs for M are 2.71 for homozygotes and 1.90
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for M. The PAF is 46.7%. These data show that the observed
GRRs for M are essentially lower than the true GRRs for the
causative allele. Moreover, a dominant causative allele may result
in non-dominant associations between the marker and the disease.
In fact, the penetrance mode of M in Table 1 is close to additive.
Fig. 2 shows the relationship between the PAF and ls
attributable to a causative allele and to a linked marker SNP.
The obvious message from the graph is that, when D9=1.0, the
PAFs explained by the causative allele and by the marker are
equal. The relationship between ls and PAF is non-linear, the
relative difference between GRR and ls for C over M increasing
towards higher PAFs. The dependence of the relationship between
PAF and ls on the frequency of the marker, the frequency of the
causative allele, the inheritance mode of the causative allele and
the extent of linkage disequilibrium is presented in the supporting
information. In the supplementary figures, the top panels
reproduces always Fig. 1, while the bottom panels show the effect
of changing one parameter value at a time. When the frequency
difference between M and C decreases to less that 1/10, the
relative difference in their ls decreases (Fig. S1 and Fig. S2). When
the penetrance mode of C is recessive, the relative difference
between ls for C and M becomes very large (Fig. S3). When the
linkage between M and C is incomplete (D9=0.9) the explained
PAF by M and C differ (Fig. S4).
Discussion
The first-generation WGA studies have been very successful and
by March 2008 it has been estimated that some 100 loci have been
associated with an increased risk of complex diseases [20].
However, in the midst of the jubilee, challenging questions are
emerging. First, as many newly discovered loci lack a demon-
strated function, the underlying mechanisms remain to be
established. Second, the reported GRRs are small and they tend
to decrease in the verification analysis, probably because in the
Figure 1. Use of a marker allele M to identify a causative locus C in genetic association studies. The frequency of M is pM=0.5; the
frequency of C is pC=0.05; the coverage of C by M is complete (with D9=1.0). The genotype and haplotype frequencies are shown for the assumed
parameters.
doi:10.1371/journal.pone.0002504.g001
CDCV & Familial Risks
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2504relatively small initial WGA study chance contributed to the
GRRs of the SNP selected for the verification, a phenomenon
called ‘winner’s curse’ or ‘the Beavis effect’ [11,21]. When the
GRRs are well below 1.5 there is a possibility of bias through an
unmeasured environmental factor, as discussed in the context of
nicotinic acetylcholine receptor and lung cancer risk [20]. Third,
the results have shown the apparent discrepancy between the high
PAF and the low ls, as discussed in the Introduction. Any positive
results from the current WGA studies will have PAFs in excess of
5–10% because the WGA platforms contain HapMap described
SNPs of high allele frequency (.5%) [19]. Even the ‘classical’
high-risk disease susceptibility genes explain a minor proportion of
the observed familial aggregation for most diseases [3,18]. For
example, the high penetrant breast cancer genes, including
BRCA1/2, are thought to explain less than 25% of the familial
risk [12]. Similarly, the Wellcome Trust Case Control Consortium
concludes that ‘‘the association signals so far identified account for
only a small proportion of overall familiality’’ [3].
Table 1. Genotype relative risk (GRR), familial risk (sibling relative risk ls) and population attributable fraction (PAF) related to a
marker M in linkage disequilibrium with a causative allele C.
Genotype relative risk (GRR) Familial risk (ls) PAF (%)
Causative allele C Marker allele M Causative allele C Marker allele M
GRRC_Hom=GRRC_Het GRRM_Hom GRRM_Het ls ls
11 1 1 1 0
1.5 1.10 1.05 1.01 1.00 4.6
2 1.19 1.10 1.04 1.00 8.9
5 1.76 1.40 1.36 1.02 28.1
10 2.71 1.90 2.00 1.05 46.7
20 4.61 2.90 2.93 1.10 64.9
50 10.31 5.90 4.12 1.16 82.7
100 19.81 10.9 4.75 1.20 90.6
The assumed parameters are pM=0.5, pC=0.05, dominant penetrance for the causative allele (GRRC_Hom=GRRC_Het)a n dD 9=1.0.
doi:10.1371/journal.pone.0002504.t001
Figure 2. Relationship between the population attributable fraction (PAF) and the sibling relative risk (ls) for a causative locus C
and marker allele M. The assumed parameters were pM=0.5, pC=0.05, dominant inheritance for C and D9=1.0.
doi:10.1371/journal.pone.0002504.g002
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from GWA studies relating to the familial risk. Some association
signals from loci of unknown function are likely to be markers of
rarer causative variants which contribute significantly to the
familial aggregation of the particular disease. Importantly, the ls
of the causative and the marker loci are variable but their
conferred PAFs remain identical if D9,1.0. Thus the low familial
risks for many of the replicated loci probably signal that they are
markers of yet unidentified causative alleles.
Some recent studies support our hypothesis. For example, the
NOD2 gene, which was the first identified susceptibility gene for
Crohn disease [22], carries three susceptibility variants which
account for most of the observed effects [23]. Two of the three
variants are covered by the marker SNP (rs17221417) with
D9=1.0. In the study of the Wellcome Trust Case Control
Consortium, the GRR for Crohn disease was 1.92 for homozygote
and 1.29 for heterozygote carriers [3]. The allele frequency of the
SNP was 0.287, which results in ls=1.02. By contrast, the familial
risk attributable to variants in the NOD2 locus has been estimated
to range from 1.19 to 1.49, depending on the population
prevalence of the mutant alleles [23,24]. This example illustrates
the large difference in familial risks explained by markers and
causative variants. It also shows that a single SNP, even a tagging
SNP, may not capture all the genetic effects of the gene, thus
causing an underestimation of the related familial risk.
Another important point from the present calculations is that
the penetrance mode of the causative variant is very difficult to
deduce from the apparent penetrance mode of the marker locus.
Many of the published WGA studies discuss the apparent
penetrance mode of the discovered loci, which is not warranted
based on our results.
The WGA studies use linkage equilibrium between the marker
and the causative locus as a mapping concept. The present results
are a direct consequence of the mapping concept. The low ls
explained by variants detected in recent genome scans may simply
be due to their association with relatively rare causative variants.
Moreover, the apparent penetrance modes of the marker
genotypes may be misleading about those of the causative
genotypes.
Methods
Let pC represent the frequency of a causative allele C in linkage
disequilibrium with a marker SNP M. If the frequency of the
marker is denoted by pM, the distribution of the four possible
haplotypes is:
Pr CM ðÞ ~pMpCzd
Pr Cm ðÞ ~ 1{pM ðÞ pC{d
Pr cM ðÞ ~pM 1{pC ðÞ {d
Pr cm ðÞ ~ 1{pM ðÞ 1{pC ðÞ zd,
where d=D9(12pM)p C,D 9 being Lewontin’s measure of linkage
disequilibrium (see Figure 1 in the main text illustrating the
concept of association between two alleles).
We assume that, given the genotype at the causal locus, the risk
of disease is conditionally independent of the marker genotype.
For example, if k0 is the disease prevalence among individuals with
wild type genotypes (G=cM/cM), the probability that an
individual with genotype cM/cM is affected by the disease
(A=1) is given by Pr(A=1IG=cM/cM)=k0, and
Pr A~1G ~cM=cM j ðÞ ~Pr A~1G ~cM=cm j ðÞ ~
Pr A~1G ~cm=cm j ðÞ ~k0:
The relative risk of disease for homozygote carriers of C compared
to wild type genotypes is:
GRRC Hom~Pr A~1G ~CC j ðÞ =Pr A~1G ~cc j ðÞ
and the relative risk for heterozygotes compared to wild types is:
GRRC Het,~Pr A~1G ~Cc j ðÞ =Pr A~1G ~cc j ðÞ :
Then, the probability that an individual has the genotype CM/
CM and he/she is affected is given by:
Pr G~CM=CM, A~1 ðÞ ~k0 GRRC Hom Pr G~CM=CM ðÞ
~k0 GRRC Hom Pr CM ðÞ
2
Similarly,
Pr G~CM=Cm, A~1 ðÞ ~k0 GRRC Hom 2 Pr CM ðÞ Pr Cm ðÞ
Pr G~Cm=Cm, A~1 ðÞ ~k0 GRRC Hom Pr Cm ðÞ
2
Pr G~CM=cM, A~1 ðÞ ~k0 GRRC Het 2 Pr CM ðÞ Pr cM ðÞ
Pr G~CM=cm, A~1 ðÞ ~k0 GRRC Het 2 Pr CM ðÞ Pr cm ðÞ
Pr G~Cm=cM, A~1 ðÞ ~k0 GRRC Het 2 Pr Cm ðÞ Pr cM ðÞ
Pr G~Cm=cm, A~1 ðÞ ~k0 GRRC Het 2 Pr Cm ðÞ Pr cm ðÞ
Pr G~cM=cM, A~1 ðÞ ~k0 Pr cM ðÞ
2
Pr G~cM=cm, A~1 ðÞ ~k0 Pr cM ðÞ Pr cm ðÞ
Pr G~cm=cm, A~1 ðÞ ~k0 Pr cm ðÞ
2
The previous equations can be used to calculate the disease
prevalence according to the marker genotype:
kMM~ Pr G~CM=CM, A~1 ðÞ ½
zPr G~CM=cM, A~1 ðÞ zPr G~cM=cM, A~1 ðÞ   =
Pr CM ðÞ
2z2 Pr CM ðÞ Pr cM ðÞ zPr cM ðÞ
2
hi
kMm~ Pr G~CM=Cm, A~1 ðÞ zPr G~CM=cm, A~1 ðÞ ½
zPr G~Cm=cM, A~1 ðÞ zPr G~cM=cm, A~1 ðÞ   =
2 Pr CM ðÞ Pr Cm ðÞ z2 Pr CM ðÞ Pr cm ðÞ ½
z2 Pr Cm ðÞ Pr cM ðÞ z2 Pr cM ðÞ Pr cm ðÞ  
kmm~ Pr G~Cm=Cm, A~1 ðÞ ½
zPr G~Cm=cm, A~1 ðÞ zPr G~cm=cm, A~1 ðÞ   =
Pr Cm ðÞ
2z2 Pr Cm ðÞ Pr cm ðÞ zPr cm ðÞ
2
hi
The genotype relative risks attributable to the marker are:
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GRRM Het~kMm=kmm
Next section describes the calculation of the population fraction
(PAF) and the familial risk (sibling recurrence risk, ls) attributable
to a causative allele C with frequency pC and genotype relative
risks GRRC_Hom and GRRC_Het. The substitution in the formulas
of the genetic parameters for the marker allele (pM, GRRM_Hom
and GRRM_Het) results in the corresponding estimates for M. The
probability that an individual in the population is wild type
homozygote (G=cc) and he is affected (A=1) is:
Pr G~cc, A~1 ðÞ ~ 1{pC ðÞ
2 k0
Similarly,
Pr G~Cc, A~1 ðÞ ~2p C 1{pC ðÞ GRRC Het k0
Pr G~CC, A~1 ðÞ ~p2
C GRRC Hom k0
The prevalence of the disease in the population is then:
k~Pr G~cc, A~1 ðÞ zPr G~Cc, A~1 ðÞ zPr G~CC, A~1 ðÞ ,
and the PAF is:
RAF~ k{k0 ðÞ =k
The sibling recurrence risk is given by:
ls~1z 1= 2 Vaz1= 4 Vd ðÞ
 
K2,
where Va is the additive genetic variance divided by k0
2,V d is the
dominancegeneticvariancedivided byk0
2 and K=k/k0.V aequals
2pC(12pC)[(12pC)(12GRRC_Het)+pC(GRRC_Het2GRRC_Hom)]
2
and Vd equals pC
2(12pC)
2[1+GRRC_Hom22GRRC_Het]
2. Note
that both the PAF and the ls are independent of the baseline
prevalence k0. Since k=k0/(12PAF), the sibling risk can be also
calculated as:
ls~ 1z 1= 2 Vaz1= 4 Vd ðÞ fg 1{PAF ðÞ
2,
Supporting Information S1 provides the code for the above
calculations.
Supporting Information
Figure S1 Dependence of the relationship between population
attributable fraction (PAF) and familial risk (ls) for a causative
allele C in linkage disequilibrium with a marker M on the
frequency of the marker pM. The assumed parameters are:
frequency of the marker allele pM=0.5 or pM=0.1, frequency of
the causative allele pC=0.05, dominant inheritance of the
causative allele (homozygous and heterozygous carriers of C are
at similar risks of disease) and D’=1.0.
Found at: doi:10.1371/journal.pone.0002504.s001 (0.03 MB TIF)
Figure S2 Dependence of the relationship between population
attributable fraction (PAF) and familial risk (ls) for a causative
allele C in linkage disequilibrium with a marker M on the
frequency of the causative allele pC. The assumed parameters are:
frequency of the marker allele pM=0.5, frequency of the causative
allele pC=0.05 or pC=0.1, dominant inheritance of the causative
allele (homozygous and heterozygous carriers of C are at similar
risks of disease) and D’=1.0.
Found at: doi:10.1371/journal.pone.0002504.s002 (0.03 MB TIF)
Figure S3 Dependence of the relationship between population
attributable fraction (PAF) and familial risk (ls) for a causative
allele C in linkage disequilibrium with a marker M on the mode of
inheritance. The assumed parameters are: frequency of the marker
allele pM=0.5, frequency of the causative allele pC=0.05,
dominant or recessive inheritance and D’=1. 0. Note the different
scaling of the two ls-axes.
Found at: doi:10.1371/journal.pone.0002504.s003 (0.03 MB TIF)
Figure S4 Dependence of the relationship between population
attributable fraction (PAF) and familial risk (ls) for a causative
allele C in linkage disequilibrium with a marker M on the linkage
disequilibrium. The assumed parameters are: frequency of the
marker allele pM=0.5, frequency of the causative allele
pC=0.05, dominant inheritance of the causative allele and
D’=1.0 or D’=0.9.
Found at: doi:10.1371/journal.pone.0002504.s004 (0.03 MB TIF)
Supporting Information S1 Code for calculation of PAFs and
ls using the free software environment R (www.r-project.org)
Found at: doi:10.1371/journal.pone.0002504.s005 (0.04 MB
DOC)
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